The JAK/STAT signaling pathway: from bench to clinic

X Hu, J Li, M Fu, X Zhao, W Wang - Signal transduction and targeted …, 2021 - nature.com
The Janus kinase/signal transducer and activator of transcription (JAK/STAT) signaling
pathway was discovered more than a quarter-century ago. As a fulcrum of many vital cellular …

Acute graft-versus-host disease

F Malard, E Holler, BM Sandmaier, H Huang… - Nature Reviews …, 2023 - nature.com
Acute graft-versus-host disease (GVHD) is a common immune complication that can occur
after allogeneic haematopoietic cell transplantation (alloHCT). Acute GVHD is a major …

[HTML][HTML] Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease

R Zeiser, N Polverelli, R Ram, SK Hashmi… - … England Journal of …, 2021 - Mass Medical Soc
Background Chronic graft-versus-host disease (GVHD), a major complication of allogeneic
stem-cell transplantation, becomes glucocorticoid-refractory or glucocorticoid-dependent in …

The 'cytokine storm': molecular mechanisms and therapeutic prospects

R Karki, TD Kanneganti - Trends in immunology, 2021 - cell.com
Cytokine storm syndrome (CSS) has generally been described as a collection of clinical
manifestations resulting from an overactivated immune system. Cytokine storms (CSs) are …

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Y Cao, J Wei, L Zou, T Jiang, G Wang, L Chen… - Journal of Allergy and …, 2020 - Elsevier
Background Accumulating evidence proposed Janus-associated kinase (JAK) inhibitors as
therapeutic targets warranting rapid investigation. Objective This study evaluated the …

Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose …

AJC Bloor, A Patel, JE Griffin, MH Gilleece, R Radia… - Nature medicine, 2020 - nature.com
The therapeutic potential of donor-derived mesenchymal stromal cells (MSCs) has been
investigated in diverse diseases, including steroid-resistant acute graft versus host disease …

Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease

R Zeiser, N von Bubnoff, J Butler, M Mohty… - … England Journal of …, 2020 - Mass Medical Soc
Background Acute graft-versus-host disease (GVHD) remains a major limitation of
allogeneic stem-cell transplantation; not all patients have a response to standard …

The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation

F La Rosée, HC Bremer, I Gehrke, A Kehr, A Hochhaus… - Leukemia, 2020 - nature.com
A subgroup of patients with severe COVID-19 suffers from progression to acute respiratory
distress syndrome and multiorgan failure. These patients present with progressive …

Rational approach toward COVID-19 main protease inhibitors via molecular docking, molecular dynamics simulation and free energy calculation

S Keretsu, SP Bhujbal, SJ Cho - Scientific reports, 2020 - nature.com
In the rapidly evolving coronavirus disease (COVID-19) pandemic, repurposing existing
drugs and evaluating commercially available inhibitors against druggable targets of the virus …

Immunomodulation in COVID-19

NE Ingraham, S Lotfi-Emran, BK Thielen… - The Lancet …, 2020 - thelancet.com
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory
syndrome corona virus 2 (SARS-CoV-2), continues to spread globally despite …